1. Barkagan, Z.S. and Momot, A.P., Diagnostika i kontroliruemaya terapiya narushenii gemostaza (Diagnosis and Controlled Therapy of Hemostasis Disorders), Moscow: N’yudiamed, 2008.
2. Berkovskii, A.L., Sergeeva, E.V., Suvorov, A.V., et al., Metody opredeleniya aktivnosti geparina. Uchebno-metodicheskoe posobie (Methods for Determining Heparin Activity), Moscow: Gos. Byudzhet. Obrazovat. Uchrezhd. Dopolnitel’nogo Prof. Obrazovaniya Ross. Med. Akad. Poslediplom. Obraz., 2015.
3. Beurskens, D.M.H., Huckriede, J.P., and Schrijver, R., et al., The anticoagulant and nonanticoagulant properties of heparin, Thromb. Haemostasis, 2020, vol. 120, no. 10, p. 1371−1383. https://doi.org/10.1055/s-0040-1715460
4. Byshevskii, A.Sh., Galyan, S.L., Kalinin, E.P., et al., Self-assembly of fibrin inhibitors of plant origin, Meditsinskaya Nauka i Obrazovanie Urala, 2012, vol. 13, no. 1, pp. 163–170.
5. Krichevskii, L.A., Low-molecular-weight heparins’ role in current strategies for controlling blood coagulation, Anaesthesia Critical Care & Pain Medicine, 2015, vol. 117, no. 16, pp. 42–48.